Law Firm Investigates Potential Securities Claims Against Boston Scientific

Bronstein, Gewirtz & Grossman says its investigation follows Boston Scientific’s October 28, 2026 third-quarter results, which missed analyst consensus for earnings per share. The company lowered sales and earnings guidance for the third consecutive quarter, citing operational challenges, cybersecurity-related remediation costs, and structural issues in its Watchman and electrophysiology segments.